A detailed history of Fny Investment Advisers, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Fny Investment Advisers, LLC holds 183,500 shares of RVNC stock, worth $471,594. This represents 0.46% of its overall portfolio holdings.

Number of Shares
183,500
Holding current value
$471,594
% of portfolio
0.46%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$2.57 - $2.57 $471,594 - $471,594
183,500 New
183,500 $952,000
Q1 2022

Apr 25, 2022

SELL
$12.36 - $20.31 $185 - $304
-15 Closed
0 $0
Q4 2021

Jan 10, 2022

BUY
$12.46 - $27.87 $186 - $418
15 New
15 $0
Q1 2020

Apr 09, 2020

SELL
$12.46 - $27.81 $12,460 - $27,810
-1,000 Closed
0 $0
Q4 2019

Jan 10, 2020

BUY
$11.66 - $20.15 $11,660 - $20,150
1,000 New
1,000 $16,000
Q3 2019

Oct 25, 2019

SELL
$10.22 - $14.5 $29,648 - $42,064
-2,901 Closed
0 $0
Q2 2019

Jul 24, 2019

BUY
$10.67 - $15.49 $30,953 - $44,936
2,901 New
2,901 $37,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Fny Investment Advisers, LLC Portfolio

Follow Fny Investment Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fny Investment Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fny Investment Advisers, LLC with notifications on news.